The proportion of clinical trials receiving approval within only one or two review rounds surged to 81% in 2026, marking a major efficiency milestone. This dramatic shift highlights the success of recent legislative efforts aimed at dismantling the bureaucratic hurdles that once defined the Brazilian clinical research landscape. During the recent “Clinical Development in LATAM: Brazil Unlocked” event in Cambridge, Massachusetts, experts from the Ministry of Health and Interfarma gathered to discuss how these changes are reshaping the country’s appeal to global sponsors. For years, Brazil was perceived as a slow-moving giant, hindered by redundant ethical reviews and unpredictable regulatory timelines. However, the current landscape reflects a modernized approach where speed and quality coexist, driven by a series of high-impact reforms. These initiatives are not merely about reducing paperwork but are part of a broader strategy to integrate Brazil into the global drug development pipeline today.
Regulatory Compliance: Accelerating Timelines Through Mandatory Deadlines
The cornerstone of this regulatory overhaul is the implementation of RDC 945/2024, a regulation that has fundamentally changed the timing of clinical trial petitions. Under this mandate, the Brazilian Health Regulatory Agency (ANVISA) is required to complete its review of clinical trial applications within a maximum of 90 business days. Perhaps the most revolutionary aspect of this reform is the “tacit approval” mechanism. This provision allows sponsors to move forward with their clinical development plans if the agency fails to provide a formal response within the specified timeframe, provided that the necessary ethical clearances have already been obtained. This shift introduces a level of predictability that was previously non-existent in the Brazilian market, effectively removing the risk of indefinite delays that once discouraged international investment. By setting a firm deadline, the government has sent a clear signal to the pharmaceutical industry that Brazil is open for business.
Beyond the 90-day cap, ANVISA has increasingly embraced the concept of regulatory reliance to streamline its internal assessment processes. This strategy involves utilizing technical evaluations and decisions made by recognized foreign regulatory authorities, such as the FDA or EMA, to avoid redundant scientific reviews in Brazil. By focusing on risk-based assessments and prioritizing studies that address urgent public health needs, the agency can allocate its resources more effectively. For global pharmaceutical sponsors, these changes necessitate a proactive operational shift. It is no longer sufficient to treat Brazil as a late-stage addition to a global study; instead, sponsors must now focus on early preparation of high-quality documentation. Strategic choices regarding regulatory pathways are essential components of trial planning today, as the agency rewards well-prepared submissions with faster processing times through these optimized assessment channels, ensuring patient access to treatments.
Ethical Reform: Implementing a Unified Review System for Multicenter Studies
The second major pillar of this transformation involves the restructuring of the ethical oversight system through Law 14.874/2024. Historically, Brazil’s research environment was characterized by a decentralized and often redundant ethical review process, where each participating institution in a multicenter study conducted its own independent assessment. This old system frequently led to conflicting queries and significant delays in trial initiation across different regions. The new legislation addresses this inefficiency by mandating a single ethical review for multicenter protocols. Under this framework, once a primary research ethics committee conducts the main review, other participating sites receive notifications rather than performing their own independent re-evaluations. This change effectively dismantles the “re-review” culture that has historically hindered the growth of large-scale clinical trials in the country, ensuring that the ethical clearance process is robust while becoming significantly more agile.
Implementing these ethical changes requires a coordinated national effort led by the Instância Nacional de Ética em Pesquisa (INAEP). This body is responsible for providing the national oversight and guidance necessary to standardize workflows across the diverse network of research committees throughout Brazil. Although the legislative framework is firmly in place, the operational transition is being handled progressively to ensure that all stakeholders are adequately trained on the new requirements. The goal is to eliminate the variance in interpretation that previously plagued the system, creating a uniform standard for ethical review regardless of where the research is conducted. By centralizing the primary assessment and providing clear guidelines for secondary sites, the government is ensuring that the protection of research participants remains paramount while removing the administrative bottlenecks that once delayed the delivery of life-saving therapies to the population.
Strategic Modernization: Measuring Performance and Future Operational Success
The impact of these reforms is best illustrated by the quantifiable improvements in ethical review timelines observed between the start of 2024 and 2026. Data from the analysis of over five hundred pharmaceutical trials reveal a consistent downward trend in the time required to secure necessary approvals. In early 2024, the median ethics review time stood at 59 business days, a figure that many sponsors still found challenging. However, by 2025, that number dropped to 52 days, and by 2026, it reached a record low of 36 business days. This reduction represents a nearly 40 percent improvement in administrative speed over a short period. Such progress indicates that the combination of legislative mandates and improved operational efficiency within the committees is delivering tangible results. For clinical trial managers, this means that the window between protocol finalization and the first patient visit has shrunk significantly, making the Brazilian market far more competitive.
The modernization of the Brazilian clinical trial landscape reached a critical turning point as the recent reforms successfully addressed long-standing barriers to entry. Stakeholders who navigated this transition recognized that internal agility became as important as regulatory speed, requiring teams to adapt their planning cycles to the new 90-day reality. Sponsors discovered that investing in local expertise and maintaining high-quality initial submissions were the most effective ways to capitalize on the “tacit approval” mechanisms and regulatory reliance pathways. Moving forward, it was clear that maintaining these gains would require a continued commitment to digital infrastructure and the training of decentralized ethics committees to prevent local bottlenecks. By streamlining the path from protocol to patient, the reforms established a new benchmark for research in Latin America. Companies that successfully integrated these changes into their global development strategies found Brazil to be a reliable partner.
